Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
GENEVA, Oct. 17, 2016 -- ObsEva SA, a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced that the Company plans to conduct an initial public offering in the United States.
This announcement is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933, as amended. As required by Rule 135, this press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
The timing and the terms of this initial public offering have not yet been determined.
Press Release: http://hugin.info/157613/R/2049240/766325.pdf
Media Contact: Liz Bryan Spectrum Science [email protected] 202-955-6222 x2526 Company Contact: Delphine Renaud ObsEva, CEO Office [email protected] +41 22 552 1550
